BioTuesdays

Tag - Matthew Kaplan

Kiora Pharma Logo

Ladenburg starts Kiora Pharma at buy; PT $6.50

Ladenburg Thalmann initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $6.50. The stock closed at 13 cents on Aug. 24. Kiora is focused on bringing treatments to the market...

Liquidia Logo

Ladenburg starts Liquidia at buy; PT $15

Ladenburg Thalmann initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $15 price target. The stock closed at $5.03 on July 21. Liquidia is a commercial-stage biotechnology company currently focused on...

Reneo Therapeutics

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

Renovacor New.jpg

Ladenburg starts Renovacor at buy; PT $22

Ladenburg Thalmann initiated coverage of Renovacor (NASDAQ:RCOR) with a “buy” rating and $22 price target. The stock closed at $7.93 on Oct. 13. Renovacor is a preclinical-stage biotech company focused on developing...

Ardelyx-2021

Ladenburg cuts Ardelyx to neutral from buy

Ladenburg Thalmann downgraded Ardelyx (NASDAQ:ARDX) to “neutral” from “buy” and removed its price target, citing an unproductive post-complete response letter (CRL) Type A meeting with the FDA. The stock closed at $1.09...

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

Cogent Biosciences Logo

Ladenburg starts Cogent Biosciences at buy; PT $4

Ladenburg Thalmann launched coverage of Cogent Biosciences (NASDAQ:COGT) with a “buy” rating and $4 price target. The stock closed at $2.89 on Oct. 13. Cogent has a late-stage clinical asset, CGT9486, in development for...

Eyenovia Logo

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

Allena Pharmaceuticals Logo

Ladenburg lowers Allena Pharma PT to $13 from $23

Ladenburg Thalmann lowered its price target for Allena Pharmaceuticals (NASDAQ:ALNA) to $13 from $23 largely driven by an increase in the number of shares outstanding, assuming an equity financing. The stock closed at...

Avadel Logo

Ladenburg ups PT for Avadel Pharma to $14 from $8

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $14 from $8 after the company completed enrollment in its REST-ON Phase 3 study, with a pivotal data readout expected in the second...